Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2011

Shire, Shionogi Ink Co-Development Agreement for ADHD Drugs in Japan

  • Intent on tapping one of the world’s fastest-growing markets for ADHD treatments, Shire and Japan’s Shionogi & Co. agreed to co-develop and co-commercialize some of Shire’s medicines for the psychiatric behavioral disorder. Upon approval of medicines for Japan, Shionogi will pay a one-time fee and share costs with Shire.

     

    Shire’s drugs for ADHD include Adderall XR, Intuniv, Vyvanse. All three recorded double-digit year-over-year sales gains during the third quarter, with the first two increasing by 50%, and Vyvanse, by 32%. Shionogi develops medicines for the central nervous system, among other therapeutic areas.

     

    The agreement comes nearly three years after Shire opened a representative office in Japan, with the goal of stepping up commercialization of its pipeline products in Japan, the world’s second largest biopharmaceutical market.

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »